Alimera Sciences, Inc. (NASDAQ:ALIM) insider Richard S. Eiswirth, Jr. sold 14,494 shares of Alimera Sciences stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total transaction of $17,827.62. Following the transaction, the insider now owns 98,619 shares of the company’s stock, valued at $121,301.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Alimera Sciences, Inc. (NASDAQ:ALIM) remained flat at $$1.24 on Thursday. 283,499 shares of the stock traded hands, compared to its average volume of 168,400. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. Alimera Sciences, Inc. has a 1 year low of $1.11 and a 1 year high of $1.72. The company has a market capitalization of $85.74, a P/E ratio of -4.00 and a beta of 2.15.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. analysts predict that Alimera Sciences, Inc. will post -0.27 EPS for the current year.

An institutional investor recently raised its position in Alimera Sciences stock. PNC Financial Services Group Inc. lifted its position in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) by 24.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 180,300 shares of the biopharmaceutical company’s stock after purchasing an additional 35,200 shares during the period. PNC Financial Services Group Inc. owned 0.28% of Alimera Sciences worth $251,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 41.78% of the company’s stock.

A number of brokerages have recently issued reports on ALIM. ValuEngine cut shares of Alimera Sciences from a “sell” rating to a “strong sell” rating in a report on Sunday, December 3rd. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Alimera Sciences in a report on Wednesday, November 22nd. Zacks Investment Research upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Monday, January 8th. Finally, Cowen reiterated a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Alimera Sciences has an average rating of “Hold” and an average target price of $3.38.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.